The Global Market for D-Amino Acids is Forecast to Reach US$5.5 Billion by 2022
Growing Role Played By Organic Chemistry in the
Pharmaceutical Industry Drives Opportunities for D-Amino Acids in Drug
Manufacturing, According to a New Report by Global Industry Analysts, Inc.
GIA launches comprehensive
analysis of industry segments, trends, growth drivers, market share, size and
demand forecasts on the global D-Amino Acids market. The global market for D-Amino Acids is forecast to
reach US$5.5 billion by 2022, driven
by its growing role as biologically important organic compounds in pharmaceutical
drug production; increase in research and development activities and emerging
new industrial applications.
Amino acids, the building
blocks of human body, occur in two sterioisomeric forms, namely L-amino acids
and D-amino acids. While L-amino acids are associated with making proteins in
the human body, D-amino acids are considered as essential intermediates in the
production of various pharmaceuticals, chemicals, agrochemicals, and food &
feed additives. Found in bacterial proteoglycan cell walls and in several
peptide antibiotics, D-amino acids are capable of addressing specific demands
of human body. Few exotic marine invertebrates and insects have D-amino acids
in their cellular fluids, while some plants also contain D-amino acids. With
several scientific discoveries offering support to the highly significant role
played by D-amino acids in the pharmaceutical and food applications, there are robust
opportunities in store over the coming years.
The global market is
forecast to grow at a rapid pace, driven by the expanding scope of end-use applications.
Pharmaceuticals segment represents the largest end-use sector, with D-amino
acids being a major constituent in the manufacture of antibiotics,
peptidoglycans, siderophores and surfactins. D-amino acids also find use in the
semi-synthesis of cephadroxyl, amoxicillin, ampicillin and others. D-amino
acids, such as D-Cysteine and D-Serine, are widely used in pharmaceutical
products for production of anti-cancer agents such as goserelin and antibiotics
such as penicillin. With spending on medicines continuing to grow, consumption
of D-amino acids in the pharmaceutical sector is expected to record steady
growth. Biopharmaceutical research holds immense potential for D-amino acids in the
coming years. Also driving growth in the market is the increasing demand for
animal feed as well as processed foods. Research & development plays a
critical role in expanding the applications of D-amino acid in the
pharmaceutical and industrial sectors.
As stated by the new
market research report on D-Amino Acids,
Asia-Pacific represents the largest and the fastest growing market, worldwide
led by factors such as growing generic drug manufacturing activity; expansion
of the manufacturing base and rise in industrial production in developing Asian
economies; and growing research and development activity.
Major players covered in
the report include Adisseo France S.A.S, Ajinomoto Co. Inc., AnaSpec Inc.,
Evonik Industries AG, IRIS Biotech GmbH, LifeSpan Biosciences Inc., Novus
Biologicals LLC, Sekisui Medical Co. Ltd., Shanghai Hanhong Chemical Co. Ltd.,
Sichuan Tongsheng Amino acid Co. Ltd., Sigma-Aldrich Co. LLC., Sumitomo
Chemical Company Limited, TCI America Inc., Tocris Bioscience, and Zhangjiagang
Huachang Pharmaceutical Co. Ltd., among others.
The research report titled
“D-Amino Acids: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides
a comprehensive review of market
trends, issues, drivers, mergers, acquisitions and other strategic industry
activities of global companies. The report provides market estimates and
projections for all major geographic markets such as the US, Canada, Japan, Europe
(France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific
(China and Rest of Asia-Pacific), Middle East & Africa and Latin America.
The market for D-amino acids is analyzed by the following End-Use Applications
– Industrial, Pharmaceutical and Others.
Global Industry
Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.
L-Ornithine is a non-essential amino acid, metabolized to generate L-arginine, which is further incorporated into proteins. α-Ketoglutarate is a key intermediate in the Krebs cycle, coming after isocitrate and before succinyl CoA. L-Ornithine α-Ketoglutarate Monohydrate
ReplyDelete